Latest Mayne Pharma (ASX:MYX) News

The Takeovers Panel has declared unacceptable circumstances in the Mayne Pharma acquisition, ordering Cosette Pharmaceuticals to comply with conditions preventing closure of the Salisbury manufacturing site. This ruling highlights concerns over market transparency and the integrity of the takeover process.

Mayne Pharma updates investors on the extended FIRB approval deadline and potential financing hurdles in its proposed acquisition by Cosette Pharmaceuticals.

The Takeovers Panel has intervened in the Mayne Pharma and Cosette Pharmaceuticals scheme, issuing interim orders that extend the deal deadline and restrict termination rights to maintain the status quo.

The Foreign Investment Review Board has extended its deadline for approving Mayne Pharma's acquisition by Cosette Pharmaceuticals, maintaining the current transaction timetable for now.

The FDA's removal of the black box warning on hormone replacement therapies marks a pivotal shift for Mayne Pharma, potentially unlocking new market opportunities and reshaping women’s health treatment.

Mayne Pharma has received notice of Cosette Pharmaceuticals' intention to appeal a court ruling in their acquisition dispute, potentially delaying the proposed takeover. The legal saga continues as key approvals and hearings loom.

Mayne Pharma’s acquisition by Cosette Pharmaceuticals faces a regulatory delay as the Foreign Investment Review Board extends its approval deadline, pushing the court hearing to mid-November.

Mayne Pharma updates shareholders on the extended Foreign Investment Review Board approval deadline and the rescheduled court hearing for its acquisition scheme by Cosette Australia BidCo.

The Treasurer has expressed preliminary concerns that Cosette Pharmaceuticals’ proposed acquisition of Mayne Pharma could harm Australia’s economy, citing plans to close a key Adelaide manufacturing site. Mayne Pharma disputes these claims and urges a resolution before the scheme deadline.

Mayne Pharma has announced the rescheduling of its Supreme Court hearing to November 3, 2025, to approve the acquisition scheme by Cosette Australia BidCo, pending Foreign Investment Review Board approval.

Mayne Pharma’s planned acquisition by Cosette Pharmaceuticals faces a delay as the Foreign Investment Review Board postpones its decision, potentially pushing back key court proceedings.

Mayne Pharma has won a key legal battle against Cosette Pharmaceuticals, clearing the way for its acquisition scheme to proceed pending final approvals. Shareholders can expect the deal to move forward with payments scheduled soon.